Novo Nordisk A/S is trading 4.3% up at $45.41 following reports that the company plans to seek Chinese regulatory approval for an oral version of its weight-loss drug Wegovy.
- The potential expansion into the Chinese market for oral obesity treatments is expected to significantly increase the company's addressable market and intensify competition with Eli Lilly.
- Positive sentiment is further supported by a slight uptick in broader equity futures, providing a mild macroeconomic tailwind for the stock during pre-market trading.